Market Risers: Admiral Group, Applied Graphene Materials, Associated British Foods, AstraZeneca

Applied Graphene Materials PLC

Stock in Admiral Group with EPIC code: LON:ADM has moved up 2.43% or 50 points throughout today’s trading session so far. Traders have remained optimistic during the trading session. The period high was 2111 dipping to 2069. The total volume of shares exchanged so far has reached 150,444 with the daily average number around 620,260. The 52 week high for the shares is 2300 about 240 points difference from the previous close and the 52 week low at 1912.5 making a difference of 147.5 points. Admiral Group now has a 20 SMA at 2059.81 and the 50 day moving average at 2084.42. This puts the market capitalisation now at £6,196.78m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for Admiral Group being recorded at Friday, November 22, 2019 at 12:58:32 PM GMT with the stock price trading at 2110 GBX.

Shares in Applied Graphene Materials with EPIC code: LON:AGM has increased 5.45% or 0.9 points during the course of today’s session so far. Buyers seem confident throughout the trading session. The periods high has reached 17.4 dropping as low as 16.95. Volume total for shares traded during this period was 20,620 whilst the average number of shares exchanged is 81,355. A 52 week share price high is 43 amounting to 26.5 points different to the previous business close and a 52 week low sitting at 15 which is a variance of 1.5 points. Applied Graphene Materials has a 20 SMA of 18.21 with a 50 day SMA of 19.31. The market cap now stands at £8.60m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Applied Graphene Materials being recorded at Friday, November 22, 2019 at 11:08:52 AM GMT with the stock price trading at 17.4 GBX.

Shares of Associated British Foods with company EPIC: LON:ABF has risen 2.02% or 50 points throughout today’s trading session so far. Market buyers have stayed positive during this period. The high for the period has reached 2538 meanwhile the session low reached 2479. The total volume traded so far comes to 228,565 with the daily average at 1,284,944. The 52 week high for the share price is 2587 some 109 points different to the previous business close and a 52 week low sitting at 2011 is a variance of 467 points. Associated British Foods now has a 20 simple moving average of 2382.79 and now a 50 day moving average of 2316.54. This puts the market cap at £20,013.52m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Associated British Foods being recorded at Friday, November 22, 2019 at 12:58:55 PM GMT with the stock price trading at 2528 GBX.

Shares of AstraZeneca with ticker code: LON:AZN has gained 2.59% or 190 points in today’s trading session so far. Market buyers are a positive bunch throughout the session. The high for the period has reached 7543 dropping as low as 7337. The number of shares traded by this point in time totalled 796,158 with the daily average number around 1,920,740. The 52 week high for the shares is 7646 about 310 points in difference on the previous days close and a 52 week low being 5312 which is a variance of 2024 points. AstraZeneca now has a 20 simple moving average of 7453.52 with a 50 day simple moving average now at 7256.45. The current market capitalisation is £98,747.06m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, November 22, 2019 at 12:58:11 PM GMT with the stock price trading at 7526 GBX.

Share on:
Find more news, interviews, share price & company profile here for:
AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases.
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

Search

Search